Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
INSPIRE PHARMACEUTICALS INC (ISPH)
|
Add to portfolio |
|
|
|
| Price: |
$4.99
| | Metrics |
| OS: |
42.2
|
M
| |
-48
|
% ROE
|
| Market cap: |
$211
|
M
| |
-70
|
% ROIC
|
|
Net cash:
|
$77.2
|
M
| |
$1.83
|
per share
|
|
EV:
|
$134
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($23.6)
|
M
| |
|
|
|
EBIT
|
($26.8)
|
M
| |
|
|
| EPS |
($0.46)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 |
| Revenues | 106.4 | 92.2 | 70.5 | 48.7 | 37.1 | 23.3 | 11.1 | 5.2 |
| Revenue growth | 15.5% | 30.7% | 44.9% | 31.3% | 59.3% | 110.2% | 112.8% | 6.5% |
| Cost of goods sold | 14.9 | 11.3 | 6.4 | 1.6 | 0.0 | 0.0 | 30.9 | 9.8 |
| Gross profit | 91.5 | 80.9 | 64.1 | 47.0 | 37.1 | 23.3 | -19.8 | -4.6 |
| Gross margin | 86.0% | 87.8% | 90.9% | 96.7% | 100.0% | 100.0% | -179.1% | -89.2% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 50.2 | 49.3 | 54.6 | 45.5 | 25.3 | 23.2 | 21.8 | 2.8 |
| General and administrative | 30.9 | 16.1 | 14.5 | 14.0 | 15.9 | 12.0 | 9.0 | 7.0 |
| EBITA | -34.0 | -33.7 | -47.5 | -64.1 | -46.4 | -35.3 | -45.3 | -31.9 |
| EBITA margin | -32.0% | -36.5% | -67.4% | -131.7% | -125.2% | -151.8% | -409.4% | -612.9% |
| Amortization of intangibles | 1.8 | 2.0 | 2.1 | 1.8 | 0.2 | 0.2 | 0.2 | 0.4 |
| EBIT | -35.8 | -35.6 | -49.7 | -65.9 | -46.6 | -35.5 | -45.5 | -32.3 |
| EBIT margin | -33.6% | -38.6% | -70.4% | -135.4% | -125.8% | -152.7% | -411.3% | -620.6% |
| Pre-tax income | -35.4 | -40.0 | -51.6 | -63.7 | -42.1 | -31.8 | -44.1 | -31.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -35.4 | -40.0 | -51.6 | -63.7 | -42.1 | -31.8 | -44.1 | -31.4 |
| Net margin | -33.3% | -43.4% | -73.2% | -131.0% | -113.6% | -136.9% | -398.2% | -603.8% |
| |
| Diluted EPS | ($0.43) | ($0.60) | ($0.91) | ($1.42) | ($1.00) | ($0.76) | ($1.25) | ($1.03) |
| Shares outstanding (diluted) | 82.7 | 66.8 | 56.6 | 44.8 | 42.2 | 42.1 | 35.3 | 30.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|